CVF2011-Where Global and Chinese Domestic Vaccine Giants Converge to Discuss Industry Redhots and New Business Opportunities |
What do China’s "Twelfth Five-Year Plan" and new GMP regulation ring to domestic and foreign vaccine players? How to align vaccine development strategies with changing business landscape? Centered around the topic of "New GMP: Developing Safe, Reliable, High Yield Vaccines for a Healthier World ", CVF2011 will track various focus points on vaccines for infectious diseases, non-infectious diseases, AIDS vaccines, cancer vaccines, RNA/DNA vaccines, and point to the best opportunities for R&D partnering and manufacturing excellence. By the present of senior officials from Ministry of Health, PRC, SFDA/ FDA, NICPBP to address the latest regulatory issues on development of China vaccine industry. Through two days’ various sessions such as keynote presentations, interactive panel discussions, case studies, cocktail party and scheduled one-to-one business meetings, you will hear the perspectives of both Chinese and MNC vaccine leaders. They will provide insights into their own company strategies for the coming years and how each perceives the marketplace developments. It will help you to win the vaccine market competition and strengthen your company’s dynamic growth in China’s vaccine market. |
Distinguished Speakers Including: |
Dr. Jean-Denis Shu Medical Director Sanofi Pasteur |
Jin Yulan President Changchun Biological Products Institute |
||
Dr. Nicholas Jackson Sr Director, Vaccine Research Pfizer |
Sam Liao Asia Head of Business Development & Licensing Novartis Vaccines & Diagnostics |
||
Dr. Sean Du Executive Director, Vaccine Research Simcere Pharmaceutical |
Dr. Li Shi CEO Shanghai Zerun Biotech Co., Ltd |
||
Prof.Tim Hirst Executive Chairman Gamma Vaccines |
James Zhao Partner Vivo Ventures |
||
Dr. Aleš Štrancar CEO BIA Separations |
Dr. Li Xiaoqiang General Manager TASLY & JENNER (Tianjin) Co., LTD |
||
Li Bo Director National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) |
Shen Xinliang Director-General National Vaccine & Serum Institute & National Engineering Research Center for Novel Vaccines |
||
Damian Thornton Director,Business Development M+W Group |
Zheng Haifa President Beijing Minhai Biotechnology Co., Ltd |
FEATURES of CVF 2011 |
Official Guideline Panel: Official Guideline Panel is where senior officials from SFDA, FDA, CCDC and NICPBP will blueprint the clearer views on the updated government policies and development prospects of China's vaccine industry. You will have the unique chance to raise your concerns and have your burning questions answered. R&D Focused Stream: R&D Stream is where vaccine experts from pharmas and biotechs will discuss the latest vaccine development in the industry. They will provide insights into their own company’s vaccine R&D strategies for the coming years and cover updates on adjuvants and delivery technologies for vaccines. Manufacturing Focused Stream: Manufacturing Stream will address the new GMP compliance issue, safety evaluation and quality control over vaccines, and how to leverage on technology and equipment advancements for optimized vaccine bioprocessing and production. Pre-scheduled One-to-One Meetings: CDMC online partnering system allows you to easily pre-arrange meetings online with potential partners before coming to the forum, to have private conversations and to make deals on site. Vaccine Service Exhibition: An international exhibition of global vaccine fraternity to showcase their products, services and technologies. |
FACTS & FIGURES |
|
TESTIMONIALS: |
WHO SHOULD ATTEND? |
Download |
CDMC Partnering Online System |
Choose your language |
Organized by |
Endorsers |
Presentation Sponsors |
Exhibition Sponsors |
Media |